{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000024","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.479478+00:00","generated_at":"2026-05-31T23:28:43.755634+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AbbVie lowers 2024 adjusted EPS guidance to $10.61-$10.81 on $937M IPR&D charge","bullets":["Preliminary Q2 2024 acquired IPR&D and milestones expense of $937 million pre-tax.","GAAP and adjusted non-GAAP diluted EPS each reduced by $0.52 in Q2.","Q2 2024 adjusted diluted EPS guidance set at $2.53-$2.57.","Full-year 2024 adjusted diluted EPS guidance lowered to $10.61-$10.81 from $11.13-$11.33.","Guidance excludes any future IPR&D expense beyond Q2; final Q2 results subject to closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000024","json":"https://secwatch.observer/filing/0001551152-24-000024.json","markdown":"https://secwatch.observer/filing/0001551152-24-000024.md","text":"https://secwatch.observer/filing/0001551152-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000024/0001551152-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000024/abbv-20240703.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:28:43.755634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}